„Twinkretyna” przyszłością leczenia cukrzycy typu 2?

Mitchel L. Zoler. Twincretin Shows Positive Effects in Phase 3 Trial in Diabetes. Medscape

Tirzepatide, a novel drug that acts via two related but separate pathways of glucose control, produced positive effects in top-line results from the phase 3, placebo-controlled study SURPASS-1 in 478 adults with type 2 diabetes, according to a December 9 press release …

The tirzepatide molecule exerts agonist effects at both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, and has been called a „twincretin”

Medscape, 9 grudnia 2020

0 replies on “„Twinkretyna” przyszłością leczenia cukrzycy typu 2?”